ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND

被引：3
|
作者：
Bozzarelli, S. [1 ]
Rimassa, L. [1 ]
Giordano, L. [1 ]
Garassino, I. [1 ]
Marrari, A. [1 ]
Tronconi, M. C. [1 ]
De Sanctis, R. M. [1 ]
Cavina, R. [1 ]
Baretti, M. [1 ]
Personeni, N. [1 ]
Pressiani, T. [1 ]
Santoro, A. [1 ]
机构：
[1] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Rozzano, MI, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv348.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
R59
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [1] An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort
    Bozzarelli, S.
    Rimassa, L.
    Giordano, L.
    Sala, S.
    Tronconi, M. C.
    Baretti, M.
    Personeni, N.
    Pressiani, T.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
    Bozzarelli, S.
    Rimassa, L.
    Giordano, L.
    Sala, S.
    Tronconi, M. C.
    Baretti, M.
    Personeni, N.
    Pressiani, T.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
    Van Cutsem, Eric
    Martinelli, Erika
    Cascinu, Stefano
    Sobrero, Alberto
    Banzi, Maria
    Seitz, Jean-Francois
    Barone, Carlo
    Ychou, Marc
    Peeters, Marc
    Brenner, Baruch
    Hofheinz, Ralf Dieter
    Maiello, Evaristo
    Andre, Thierry
    Spallanzani, Andrea
    Garcia-Carbonero, Rocio
    Arriaga, Yull E.
    Verma, Udit
    Grothey, Axel
    Kappeler, Christian
    Miriyala, Ashok
    Kalmus, Joachim
    Falcone, Alfredo
    Zaniboni, Alberto
    ONCOLOGIST, 2019, 24 (02): : 185 - 192
  • [4] An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)
    Dane, F.
    Ozgurdal, K.
    Yalcin, S.
    Benekli, M.
    Aykan, N. F.
    Yucel, I.
    Ozkan, M.
    Evrensel, T.
    Sevinc, A.
    Coskun, H. S.
    Sanli, U. S.
    Kara, I. O.
    ANNALS OF ONCOLOGY, 2015, 26
  • [5] Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy
    Kudo, T.
    Kato, T.
    Kagawa, Y.
    Murata, K.
    Ohta, H.
    Noura, S.
    Hasegawa, J.
    Tamagawa, H.
    Ohta, K.
    Ikenaga, M.
    Miyazaki, S.
    Komori, T.
    Nishimura, J.
    Hata, T.
    Matsuda, C.
    Satoh, T.
    Mizushima, T.
    Yamamoto, H.
    Doki, Y.
    Mori, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] CONSIGN - an open-label phase-3B-study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy
    Hofheinz, R. -D
    Glardello, F.
    Seitz, J-F
    Verma, U.
    Garcia-Carbonero, R.
    Grothey, A.
    Miriyala, A.
    Kalmus, J.
    Shapiro, J.
    Falcone, A.
    Zanibonl, A.
    van Cutsem, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 10 - 10
  • [7] CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy
    Van Cutsem, E.
    Ciardiello, F.
    Seitz, J. F.
    Hofheinz, R. D.
    Verma, U.
    Garcia-Carbonero, R.
    Grothey, A.
    Miriyala, A.
    Kalmus, J.
    Shapiro, J.
    Falcone, A.
    Zaniboni, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S378 - S379
  • [8] A multicenter, open-label, phase 2 study of Imprime PGG and pembrolizumab in patients with metastatic breast cancer who have progressed through prior hormonal therapy
    Stopeck, Alison
    Gargano, Michele
    Bose, Nandita
    Niles, Nick
    Chisamore, Michael
    Iglesias, Jose
    CANCER RESEARCH, 2022, 82 (04)
  • [9] Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy
    Kudo, Toshihiro
    Kato, Takeshi
    Kagawa, Yoshinori
    Sakai, Daisuke
    Satoh, Taroh
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] Phase II Dose Titration Study of Regorafenib for Patients With Unresectable Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 18 - 19
12345